Market Overview

UPDATE: Credit Suisse Initiates Arena Pharmaceuticals at Underperform on Belviq Expectations

Share:
Related ARNA
18 Biggest Mid-Day Gainers For Wednesday
20 Stocks Moving In Wednesday's Pre-Market Session
Arena Pharmaceuticals (ARNA) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow (Seeking Alpha)

Credit Suisse initiated its Arena Pharmaceuticals (NASDAQ: ARNA) at Underperform with a $6 price target.

Credit Suisse noted, "We are initiating with an Underperform rating and a $6 target price. ARNA commendably ushered Belviq through FDA; we believe that sales (ARNA has a ~35% royalty) will fall short of the market's lofty expectations."

Arena Pharmaceuticals closed at $9.16 on Wednesday.

Latest Ratings for ARNA

DateFirmActionFromTo
Sep 2016FBR CapitalInitiates Coverage onOutperform
Nov 2013WallachbethInitiates Coverage onBuy
Oct 2013Cowen & Co.Initiates Coverage onMarket Perform

View More Analyst Ratings for ARNA
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (ARNA)

View Comments and Join the Discussion!